# US 2013/0280815 A1 · Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280815 A1
- Document ID: US20130280815A1
- Status: Published application
- Kind: A1
- Application number: 13/866,164
- Filed: 2013-04-19
- Published: 2013-10-24
- Earliest claimed: 2012-04-19
- Assignees: ProteinSimple
- Applicants: Proteinsimple
- Inventors: Jiaqi Wu
- Web page: https://patentgrep.com/patent/US20130280815A1

## CPC

- G01N 21/25: Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- G01N 21/31: Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry {(G01N21/72 takes precedence)}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6857: {Antibody fragments}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are IEF focusing methods for determining the number of drug molecules present in at least one antibody-drug conjugate (ADC) species subpopulation. In one embodiment, the method comprises performing free solution isoelectric focusing on a sample comprising at least one ADC species, to obtain a focused sample. The absorbance of the sample at two different wavelengths is then measured, for example, over a range of pI values. Absorbance values at the two different wavelengths are compared at at least one corresponding pI value, where the at least one corresponding pI value is the pI of the ADC subpopulation. The number of drug molecules in the at least one ADC species subpopulation is then determined based on the comparison. The methods provided herein can also be used to determine the number of specific binding pair members bound to its target specific binding pair member.

## Claims

### Claim 1

A method for determining the number of drug molecules present in at least one antibody-drug conjugate (ADC) species subpopulation, in a sample comprising at least one ADC species, comprising:
performing free solution isoelectric focusing on the sample to obtain a focused sample;
measuring the absorbance of the focused sample over a range of isoelectric points at two different wavelengths;
comparing the absorbance values at the two different wavelengths at at least one corresponding pI value, wherein the at least one corresponding pI value is the pI of the ADC subpopulation; and
determining the number of drug molecules in the at least one ADC species subpopulation based on the comparison.

### Claim 2 (depends on 1)

The method of claim 1, wherein the free solution isoelectric focusing is performed in a capillary tube.

### Claim 3 (depends on 1)

The method of claim 1, wherein the free solution isoelectric focusing is performed with H3PO4 as the anolyte.

### Claim 4 (depends on 1)

The method of claim 1, wherein the free solution isoelectric focusing is performed with NaOH as the catholyte.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first wavelength is from about 220 nm to about 300 nm and the second wavelength is from about 280 nm to about 700 nm.

### Claim 6 (depends on 5)

The method of claim 5, wherein the two wavelengths are about 280 nm and about 310 nm.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody is an antibody fragment.

### Claim 8 (depends on 1)

The method of claim 1, wherein at least two antibody-drug conjugate species are present in the sample.

### Claim 9 (depends on 8)

The method of claim 8, wherein the at least two antibody-drug conjugate species comprise drug molecules with different net charges.

### Claim 10 (depends on 1)

The method of claim 1, wherein the free solution isoelectric focusing is carried out at about 100 V/cm to about 1000 V/cm.

### Claim 11 (depends on 10)

The method of claim 10, wherein the free solution isoelectric focusing is carried out for about 3 minutes to about 6 minutes.

### Claim 12 (depends on 1)

The method of claim 1, wherein the sample comprises about 5% to about 10% pH 3-10 ampholytes.

### Claim 13 (depends on 12)

The method of claim 12, wherein the sample comprises about 8% pH 3-10 ampholytes.

### Claim 14 (depends on 1)

The method of claim 1, wherein the sample comprises about 2% pH 8-10.5 ampholytes.

### Claim 15 (depends on 1)

The method of claim 1, wherein the sample comprises about 5% to about 10% pH 2-9 ampholytes.

### Claim 16 (depends on 15)

The method of claim 15, wherein the sample comprises about 8% pH 2-9 ampholytes.

### Claim 17 (depends on 1)

The method of claim 1, wherein the focused sample has a resolution of at least 0.1 pI.

### Claim 18 (depends on 1)

The method of claim 1, wherein the method further comprises a pre-focusing step at about 100 V/cm to about 1000 V/cm.

### Claim 19 (depends on 1)

The method of claim 1, wherein the sample comprises at least two internal pI markers.

### Claim 20 (depends on 19)

The method of claim 19, wherein the at least two internal pI markers are 4.22 and 9.46.

### Claim 21 (depends on 19)

The method of claim 19, wherein the at least two internal pI markers are 7.65 and 9.77.

### Claim 22 (depends on 1)

The method of claim 1, wherein the free solution isoelectric focusing is carried out in an iCE instrument.

### Claim 23 (depends on 1)

The method of claim 1, further comprising determining the number of ADC subpopulations in the sample.

### Claim 24 (depends on 23)

The method of claim 23, further comprising determining the concentration of at least one ADC subpopulation in the sample.

### Claim 25 (depends on 23)

The method of claim 23, further comprising determining the number of drug molecules present in each ADC subpopulation.

### Claim 26

A method for determining the number of specific binding pair members bound to its target specific binding pair member in a sample comprising at least one specific binding pair, comprising:
performing free solution isoelectric focusing on the sample to obtain a focused sample;
measuring the absorbance of the focused sample over a range of isoelectric points at two different wavelengths;
comparing the absorbance values at the two different wavelengths at at least one corresponding pI value, wherein the at least one corresponding pI value is the pI of the specific binding pair; and
determining the number of specific binding pair members in the at least one specific binding pair based on the comparison.

### Claim 27 (depends on 26)

The method of claim 26, wherein the free solution isoelectric focusing is performed in a capillary tube.

### Claim 28 (depends on 26)

The method of claim 26, wherein the free solution isoelectric focusing is performed with H3PO4 as the anolyte.

### Claim 29 (depends on 26)

The method of claim 26, wherein the free solution isoelectric focusing is performed with NaOH as the catholyte.

### Claim 30 (depends on 26)

The method of claim 26, wherein the first wavelength is from about 220 nm to about 300 nm and the second wavelength is from about 280 nm to about 700 nm.

### Claim 31 (depends on 30)

The method of claim 30, wherein the two wavelengths are about 280 nm and about 310 nm.

### Claim 32 (depends on 26)

The method of claim 26, wherein the free specific binding pair member is a charged antigen.

### Claim 33 (depends on 26)

The method of claim 26, wherein at least two specific binding pair species are present in the sample.

### Claim 34 (depends on 33)

The method of claim 33, wherein the at least two specific binding pair species comprise specific binding pair members with different net charges.

### Claim 35 (depends on 26)

The method of claim 26, wherein the free solution isoelectric focusing is carried out at about 100 V/cm to about 1000 V/cm.

### Claim 36 (depends on 35)

The method of claim 35, wherein the free solution isoelectric focusing is carried out for about 3 minutes to about 6 minutes.

### Claim 37 (depends on 26)

The method of claim 26, wherein the sample comprises about 5% to about 10% pH 3-10 ampholytes.

### Claim 38 (depends on 37)

The method of claim 37, wherein the sample comprises about 8% pH 3-10 ampholytes.

### Claim 39 (depends on 26)

The method of claim 26, wherein the sample comprises about 2% pH 8-10.5 ampholytes.

### Claim 40 (depends on 26)

The method of claim 26, wherein the sample comprises about 5% to about 10% pH 2-9 ampholytes.

### Claim 41 (depends on 40)

The method of claim 40, wherein the sample comprises about 8% pH 2-9 ampholytes.

### Claim 42 (depends on 26)

The method of claim 26, wherein the focused sample has a resolution of at least 0.1 pI.

### Claim 43 (depends on 26)

The method of claim 26, wherein the method further comprises a pre-focusing step at about 100 V/cm to about 1000 V/cm.

### Claim 44 (depends on 26)

The method of claim 26, wherein the sample comprises at least two internal pI markers.

### Claim 45 (depends on 44)

The method of claim 44, wherein the at least two internal pI markers are 4.22 and 9.46.

### Claim 46 (depends on 44)

The method of claim 44, wherein the at least two internal pI markers are 7.65 and 9.77.

### Claim 47 (depends on 26)

The method of claim 26, wherein the free solution isoelectric focusing is carried out in an iCE instrument.

### Claim 48 (depends on 26)

The method of claim 26, further comprising determining the number of specific binding pair subpopulations in the sample.

### Claim 49 (depends on 48)

The method of claim 48, further comprising determining the concentration of at least one specific binding pair subpopulation in the sample.

### Claim 50 (depends on 48)

The method of claim 48, further comprising determining the number of specific binding pair members present in each specific binding pair subpopulations.

### Claim 51

A method for determining the number of drug molecules in at least two ADC subpopulations in a sample comprising at least one ADC species populations, comprising:
performing free solution isoelectric focusing on the sample to obtain a focused sample;
measuring the absorbance of the focused sample over a range of isoelectric points at two different wavelengths;
comparing the absorbance values at the two different wavelengths at at least two corresponding pI values, wherein the at least two corresponding pI values are the pIs of the at least two ADC subpopulations; and
determining the number of drug molecules in the at least two ADC species subpopulation based on the comparison.

### Claim 52 (depends on 50)

The method of claim 50, wherein the free solution isoelectric focusing is performed in a capillary tube.

### Claim 53 (depends on 50)

The method of claim 50, wherein the free solution isoelectric focusing is performed with H3PO4 as the anolyte.

### Claim 54 (depends on 50)

The method of claim 50, wherein the free solution isoelectric focusing is performed with NaOH as the catholyte.

### Claim 55 (depends on 50)

The method of claim 50, wherein the first wavelength is from about 220 nm to about 300 nm and the second wavelength is from about 280 nm to about 700 nm.

### Claim 56 (depends on 55)

The method of claim 55, wherein the two wavelengths are about 280 nm and about 310 nm.

### Claim 57 (depends on 50)

The method of claim 50, wherein the antibody is an antibody fragment.

### Claim 58 (depends on 50)

The method of claim 50, wherein at least two antibody-drug conjugate species are present in the sample.

### Claim 59 (depends on 50)

The method of claim 50, wherein, the number of overlapping absorbance peaks corresponds to the number of ADC subpopulations.

### Claim 60 (depends on 51)

The method of claim 51, further comprising determining the concentration of the at least two ADC subpopulations.

### Claim 61 (depends on 1)

The method of claim 1, wherein the two different wavelengths are two different ultraviolet wavelengths.

### Claim 62 (depends on 1)

The method of claim 1, wherein the one wavelength is in the ultraviolet region of the electromagnetic spectrum and one wavelength is in the visible region of the electromagnetic spectrum.

### Claim 63 (depends on 1)

The method of claim 1, wherein the free solution isoelectric focusing is carried out at about 600 V/cm.
